We believe in supporting healthcare providers via Investigator Initiated Trials (IIT) to improve the medical and scientific knowledge of our compounds in clinical development.
ACEA Therapeutics is committed to developing and delivering novel medicines designed to improve the lives of patients with life-threatening diseases. Abivertinib, our lead investigative compound, is a dual inhibitor of the epidermal growth factor receptor (EGFR) and Bruton’s Tyrosine Kinase (BTK) receptor which is being developed for the treatment of late-stage non-small cell lung cancer (NSCLC) and B-cell lymphomas.
An IIT may be a clinical or non-clinical study for which ACEA provides funding and/or drug compound. For clinical studies, our focus is on trials that evaluate Abivertinib in adults with solid tumors or blood cancer as a stand-alone agent or in combination therapy regimens (requests outside of this area will not be considered at this time).
We support IITs that will:
- Contribute knowledge to the medical and scientific community
- Address unmet needs of patients and their healthcare providers
- Have outcomes communicated in an appropriate scientific forum, including peer-reviewed publications
Examples of appropriate requestors of IIT support include, but are not limited to:
- Healthcare providers and their institutions
- Members of the scientific community and their institutions (colleges and universities)
- Government research institutions
If you are interested in evaluating Abivertinib or any of our other pipeline compounds for potential use in the treatment of cancer or autoimmune disease, please contact us at ACEA-IIT@aceatherapeutics.com.